Core Viewpoint - Multiple companies in China conducted share buybacks on October 20, 2025, with notable activity from Mengniu Dairy, which had the largest buyback amount of 10.14 million yuan for 700,000 shares [1][2] Summary by Company - **Mengniu Dairy (02319)**: - Buyback of 700,000 shares - Total buyback amount of 10.14 million yuan - Year-to-date cumulative buyback of 1.92 million shares, representing 0.491% of total share capital [2] - **YunGongChang (N23027)**: - Buyback of 1.87 million shares - Total buyback amount of 7.53 million yuan - Year-to-date cumulative buyback of 2.45 million shares, representing 5.33% of total share capital [2] - **Lianyi Rong Technology (09959)**: - Buyback of 2.45 million shares - Total buyback amount of 7.44 million yuan - Year-to-date cumulative buyback of 6.54 million shares, representing 3.06% of total share capital [2] - **Guoshengtang (02273)**: - Buyback of 232,000 shares - Total buyback amount of 6.83 million yuan - Year-to-date cumulative buyback of 467,810 shares, representing 1.97% of total share capital [2] - **Antong Oilfield Services (03337)**: - Buyback of 4.42 million shares - Total buyback amount of 4.94 million yuan - Year-to-date cumulative buyback of 3.37 million shares, representing 1.14% of total share capital [2] - **Weishi Jiajie (00856)**: - Buyback of 500,000 shares - Total buyback amount of 4.53 million yuan - Year-to-date cumulative buyback of 663,800 shares, representing 0.462% of total share capital [2] - **Beisen Holdings (09669)**: - Buyback of 400,600 shares - Total buyback amount of 3.24 million yuan - Year-to-date cumulative buyback of 143,260 shares, representing 0.204% of total share capital [2] - **Zhongxu Future (09890)**: - Buyback of 228,200 shares - Total buyback amount of 3.13 million yuan - Year-to-date cumulative buyback of 598,580 shares, representing 1.12% of total share capital [2] - **Shoujia Technology (00103)**: - Buyback of 2.8 million shares - Total buyback amount of 2.21 million yuan - Year-to-date cumulative buyback of 5.75 million shares, representing 2.45% of total share capital [2] - **Meili Tianyuan Medical Health (02373)**: - Buyback of 70,000 shares - Total buyback amount of 2.21 million yuan - Year-to-date cumulative buyback of 30,050 shares, representing 0.127% of total share capital [2] - **Kangchen Pharmaceutical (01681)**: - Buyback of 100,000 shares - Total buyback amount of 1.54 million yuan - Year-to-date cumulative buyback of 623,200 shares, representing 7.32% of total share capital [2]

格隆汇10月20日丨药师帮(09885.HK)公告，10月20日耗资108万港元回购10万股。 ...

Core Viewpoint - The company, Yaoshi Bang (09885), has announced a share buyback plan, indicating confidence in its long-term growth and market performance, as the current stock price is perceived to be undervalued [1] Summary by Relevant Sections Share Buyback Details - On October 20, 2025, the company repurchased a total of 100,000 shares at an approximate total cost of HKD 1.0791 million, excluding commissions and other expenses, with an average repurchase price of HKD 10.7907 per share [1] - The repurchased shares will be canceled in due course [1] Management's Perspective - The board of directors believes that the current stock price does not reflect the true value of the company and its business prospects [1] - The share buyback plan is seen as a demonstration of confidence from the board and senior management regarding the company's long-term growth and market performance [1] - The board also believes that the share buyback plan is in the best interest of the company and its shareholders [1]

Core Viewpoint - The company, Yaoshi Bang (09885), has announced a share buyback plan, indicating confidence in its long-term growth and market performance, as the current stock price is perceived to be below its true value [1] Summary by Relevant Sections Share Buyback Details - The company repurchased a total of 100,000 shares on October 20, 2025, for an approximate total amount of HKD 1.0791 million, excluding commissions and other expenses [1] - The average repurchase price was HKD 10.7907 per share [1] - The repurchased shares will be canceled in due course [1] Management's Perspective - The board believes that the current stock price does not adequately reflect the company's business prospects [1] - The share buyback plan is seen as a demonstration of confidence from the board and senior management regarding the company's long-term growth and market performance [1] - The board asserts that the buyback plan is in the best interests of the company and its shareholders [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年10月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 茲提述本公司日期為2025年5月7日、2025年5月9日、2025年5月12日、2025年5月 13日、2025年5月14日、2025年5月15日、2025年5月16日、2025年5月19日、2025年5 月21日、2025年5月22日、2025年5月23日、2025年5月26日、2025年5月27日、2025 年6月4日、2025年6月5日、2025年6月11日、2025年6月17日、2025年6月23日、2025 年8月21日 及2025年10月15日的公告（「該等公告」），內 容 有 關（其 中 包 括）其股份 回 購 計 劃。本 公 司 將 根 據 市 況 及 資 金 安 排，於 市 場 上 回 購 總 額 最 多1億港元的 股 份。除 另 有 說 明 者 外，本 公 告 所 用 詞 彙 與 該 等 公 告 所 界 定 者 具 相 同 涵 ...

Group 1 - The core viewpoint of the news is that Ruize Health has completed a new round of strategic financing by introducing China Reinsurance as a significant shareholder, marking recognition of its innovative model in the "pharmaceutical + insurance" sector [1] - The collaboration is expected to create significant resource synergies, with China Reinsurance providing expertise in risk pricing and a broad insurance channel network, while Yaoshi Bang supports Ruize Health with its nationwide pharmaceutical supply chain [1] - This partnership positions Yaoshi Bang to accelerate its entry into the trillion-yuan commercial health insurance market and extend its services to end consumers covered by commercial insurance [1] Group 2 - Ruize Health has shown remarkable growth, with over 30 cooperative insurance institutions and more than 1.2 million service policies as of September 2025, reflecting a year-on-year increase of over 700% [2] - The company holds over 50% market share in the outpatient insurance segment, leading the industry, and has achieved a peak daily GMV of over 1 million yuan for commercial pharmaceutical services [2] - The introduction of China Reinsurance enhances Ruize Health's risk control and channel capabilities, further facilitating Yaoshi Bang's transition from B-end supply chain services to C-end consumer services [2]

Group 1 - The company, Yaoshi Bang (09885), announced a share buyback plan, spending HKD 1.1143 million to repurchase 100,000 shares on October 15, 2025 [1]

Group 1 - The company, Yaoshi Bang (09885), announced a share buyback plan, spending HKD 1.1143 million to repurchase 100,000 shares on October 15, 2025 [1]

Group 1 - The company, Yaoshi Bang (09885.HK), announced a share buyback on October 15, 2023, spending HKD 1.114 million to repurchase 100,000 shares [1]